{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T13:29:32Z","timestamp":1781530172888,"version":"3.54.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,4,10]],"date-time":"2017-04-10T00:00:00Z","timestamp":1491782400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,4,10]],"date-time":"2017-04-10T00:00:00Z","timestamp":1491782400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["K23 GM110516"],"award-info":[{"award-number":["K23 GM110516"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["UL1 TR001082"],"award-info":[{"award-number":["UL1 TR001082"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"name":"NIH","award":["NIH R56 DA038366"],"award-info":[{"award-number":["NIH R56 DA038366"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Med. Toxicol."],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1007\/s13181-017-0605-9","type":"journal-article","created":{"date-parts":[[2017,4,10]],"date-time":"2017-04-10T13:58:13Z","timestamp":1491832693000},"page":"146-152","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Characteristics and Treatment of Patients with Clinical Illness Due to Synthetic Cannabinoid Inhalation Reported by Medical Toxicologists: A ToxIC Database Study"],"prefix":"10.1007","volume":"13","author":[{"name":"On behalf of the ACMT Toxicology Investigators Consortium (ToxIC)","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew A.","family":"Monte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane P.","family":"Calello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy R.","family":"Gerona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eike","family":"Hamad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharan L.","family":"Campleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffery","family":"Brent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Wax","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert G.","family":"Carlson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,4,10]]},"reference":[{"key":"605_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.drugalcdep.2014.08.005","volume":"144","author":"MS Castaneto","year":"2014","unstructured":"Castaneto MS, Gorelick DA, Desrosiers NA, et al. Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications. Drug Alcohol Depend. 2014;144:12\u201341.","journal-title":"Drug Alcohol Depend"},{"issue":"9","key":"605_CR2","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.7205\/MILMED-D-12-00180","volume":"177","author":"G Loeffler","year":"2012","unstructured":"Loeffler G, Hurst D, Penn A, et al. Spice, bath salts, and the U.S. military: the emergence of synthetic cannabinoid receptor agonists and cathinones in the US Armed Forces. Mil Med. 2012;177(9):1041\u20138.","journal-title":"Mil Med"},{"key":"605_CR3","doi-asserted-by":"crossref","unstructured":"Patrick ME, O\u2019Malley PM, Kloska DD, et al. Novel psychoactive substance use by US adolescents: Characteristics associated with use of synthetic cannabinoids and synthetic cathinones. Drug Alcohol Rev. 2015.","DOI":"10.1111\/dar.12372"},{"issue":"2","key":"605_CR4","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1056\/NEJMp1505328","volume":"373","author":"J Trecki","year":"2015","unstructured":"Trecki J, Gerona RR, Schwartz MD. Synthetic cannabinoid\u2013related illnesses and deaths. NEJM. 2015;373(2):103\u20137.","journal-title":"NEJM"},{"key":"605_CR5","doi-asserted-by":"crossref","unstructured":"Castaneto MS, Wohlfarth A, Desrosiers NA, et al. Synthetic cannabinoids pharmacokinetics and detection methods in biological matrices. Drug metabolism reviews. 2015; 1\u201351.","DOI":"10.3109\/03602532.2015.1029635"},{"issue":"9","key":"605_CR6","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1021\/acschemneuro.5b00112","volume":"6","author":"SD Banister","year":"2015","unstructured":"Banister SD, Moir M, Stuart J, et al. Pharmacology of indole and indazole synthetic cannabinoid designer drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA, and 5F-ADBICA. ACS Chem Neurosci. 2015;6(9):1546\u201359.","journal-title":"ACS Chem Neurosci"},{"issue":"4","key":"605_CR7","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1056\/NEJMc1313655","volume":"370","author":"AA Monte","year":"2014","unstructured":"Monte AA, Bronstein AC, Cao DJ, et al. An outbreak of exposure to a novel synthetic cannabinoid. N Engl J Med. 2014;370(4):389\u201390.","journal-title":"N Engl J Med"},{"issue":"7","key":"605_CR8","doi-asserted-by":"publisher","first-page":"1320.e1325","DOI":"10.1016\/j.ajem.2011.05.013","volume":"30","author":"AC Young","year":"2012","unstructured":"Young AC, Schwarz E, Medina G, et al. Cardiotoxicity associated with the synthetic cannabinoid, K9, with laboratory confirmation. Am J Emerg Med. 2012;30(7):1320.e1325\u20137.","journal-title":"Am J Emerg Med"},{"key":"605_CR9","doi-asserted-by":"crossref","unstructured":"Adams AJ, Banister SD, Irizarry L, et al. \u201cZombie\u201d outbreak caused by the synthetic cannabinoid AMB-FUBINACA in New York. N Engl J Med. 2016.","DOI":"10.1056\/NEJMoa1610300"},{"issue":"5","key":"605_CR10","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/sj.bjp.0707133","volume":"150","author":"A Thomas","year":"2007","unstructured":"Thomas A, Baillie GL, Phillips AM, et al. Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br J Pharmacol. 2007;150(5):613\u201323.","journal-title":"Br J Pharmacol"},{"issue":"20","key":"605_CR11","doi-asserted-by":"publisher","first-page":"4790","DOI":"10.1111\/bph.13250","volume":"172","author":"RB Laprairie","year":"2015","unstructured":"Laprairie RB, Bagher AM, Kelly ME, et al. Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Br J Pharmacol. 2015;172(20):4790\u2013805.","journal-title":"Br J Pharmacol"},{"key":"605_CR12","doi-asserted-by":"crossref","unstructured":"Cottencin O, Rolland B, Karila L. New designer drugs (synthetic cannabinoids and synthetic cathinones): review of literature. Curr Pharm Des. 2013.","DOI":"10.2174\/13816128113199990622"},{"issue":"8","key":"605_CR13","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1021\/acschemneuro.5b00107","volume":"6","author":"SD Banister","year":"2015","unstructured":"Banister SD, Stuart J, Kevin RC, et al. Effects of bioisosteric fluorine in synthetic cannabinoid designer drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135. ACS Chem Neurosci. 2015;6(8):1445\u201358.","journal-title":"ACS Chem Neurosci"},{"issue":"4","key":"605_CR14","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.annemergmed.2012.03.007","volume":"60","author":"CO Hoyte","year":"2012","unstructured":"Hoyte CO, Jacob J, Monte AA, et al. A characterization of synthetic cannabinoid exposures reported to the National Poison Data System in 2010. Ann Emerg Med. 2012;60(4):435\u20138.","journal-title":"Ann Emerg Med"},{"key":"605_CR15","doi-asserted-by":"crossref","unstructured":"Bernson-Leung ME, Leung LY, Kumar S. Synthetic cannabis and acute ischemic stroke. J Stroke Cerebrovasc Dis. 2013.","DOI":"10.1016\/j.jstrokecerebrovasdis.2013.07.030"},{"issue":"6","key":"605_CR16","doi-asserted-by":"publisher","first-page":"e1622","DOI":"10.1542\/peds.2010-3823","volume":"128","author":"A Mir","year":"2011","unstructured":"Mir A, Obafemi A, Young A, et al. Myocardial infarction associated with use of the synthetic cannabinoid K2. Pediatrics. 2011;128(6):e1622\u20137.","journal-title":"Pediatrics"},{"issue":"4","key":"605_CR17","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s13181-011-0177-z","volume":"7","author":"PM Wax","year":"2011","unstructured":"Wax PM, Kleinschmidt KC, Brent J, et al. The toxicology investigators consortium (ToxIC) registry. J Med Toxicol. 2011;7(4):259\u201365.","journal-title":"J Med Toxicol"},{"issue":"11","key":"605_CR18","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1111\/j.1360-0443.1995.tb02812.x","volume":"90","author":"EB Adair","year":"1995","unstructured":"Adair EB, Craddock SG, Miller HG, et al. Assessing consistency of responses to questions on cocaine use. Addiction. 1995;90(11):1497\u2013502.","journal-title":"Addiction"},{"issue":"3","key":"605_CR19","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/S0376-8716(98)00028-3","volume":"51","author":"S Darke","year":"1998","unstructured":"Darke S. Self-report among injecting drug users: a review. Drug Alcohol Depend. 1998;51(3):253\u201363. discussion 267-258","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"605_CR20","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/J354v20n02_03","volume":"20","author":"SD Passik","year":"2006","unstructured":"Passik SD, Hays L, Eisner N, et al. Psychiatric and pain characteristics of prescription drug abusers entering drug rehabilitation. J Pain Palliat Care Pharmacother. 2006;20(2):5\u201313.","journal-title":"J Pain Palliat Care Pharmacother"},{"issue":"2","key":"605_CR21","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.jemermed.2012.07.061","volume":"44","author":"CR Harris","year":"2013","unstructured":"Harris CR, Brown A. Synthetic cannabinoid intoxication: a case series and review. J Emerg Med. 2013;44(2):360\u20136.","journal-title":"J Emerg Med"}],"container-title":["Journal of Medical Toxicology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13181-017-0605-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13181-017-0605-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13181-017-0605-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T02:33:13Z","timestamp":1692757993000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13181-017-0605-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,10]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["605"],"URL":"https:\/\/doi.org\/10.1007\/s13181-017-0605-9","relation":{},"ISSN":["1556-9039","1937-6995"],"issn-type":[{"value":"1556-9039","type":"print"},{"value":"1937-6995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,10]]},"assertion":[{"value":"19 October 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The contents of this work are the sole responsibility of the authors and do not necessarily represents the views of the National Institutes of Health (NIH). The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Dr. Monte receives support from NIH 1\u00a0K23 GM110516 and NIH CTSI UL1 TR001082. Dr. Monte has a patent pending for a synthetic cannabinoid clinical assay and has been awarded funding through the Department of Defense for examination of patterns of use of synthetic cannabinoids and assay development. A subset of the data collected was funded by the grant NIH R56 DA038366 (Carlson, Sheth, Boyer, PIs).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding and Financial Disclosures"}}]}}